HIGHLIGHTS
SUMMARY
An international panel of multidisciplinary experts developed recommendations for patients with liver metastases, stating that the onco-surgical treatment strategy should be directed toward resectability. Active systemic anticancer treatment has been demonstrated to be able to convert about 30% of patients with the initially-unresectable disease to liver surgery; however, there is no universal consensus or definitive dedicated randomized-controlled trials regarding the optimal chemotherapy features in terms of long-term outcomes. In this context of uncertainty regarding the impact of the type and modalities of pre-operative systemic anticancer therapy (PO-SACT) on . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.